Stratec Se (SBS.DE) Stock Price

Stratec Se Price

🇩🇪XETRA·CLOSED
17.36EUR
Market closed
Today +/-
Today %

Stratec Se (SBS.DE) Stock | ISIN DE000STRA555 | WKN STRA55. The current Stratec Se stock price is 17.36 EUR (2026). Revenue is 278.34 M EUR. Net income is 23.16 M EUR. The P/E ratio is 9.11. Market capitalization is 211.03 M EUR. Stratec Se operates in the Health sector.

Stratec Se stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Stratec Se over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stratec Se stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stratec Se's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Stratec Se Stock Price History
DateStratec Se Price
Access this data via the Eulerpool API
Get Free API Key

Stratec Se Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
47.6 M EUR
7.2 M EUR
4.4 M EUR
Jan 1, 2006
69.1 M EUR
10.8 M EUR
7.7 M EUR
Jan 1, 2007
68.3 M EUR
14.3 M EUR
10 M EUR
Jan 1, 2008
62.1 M EUR
11.3 M EUR
6.1 M EUR
Jan 1, 2009
80.3 M EUR
14.7 M EUR
11.7 M EUR
Jan 1, 2010
103.8 M EUR
17.6 M EUR
13 M EUR
Jan 1, 2011
118.7 M EUR
21.8 M EUR
15.3 M EUR
Jan 1, 2012
122.4 M EUR
17.6 M EUR
14 M EUR
Jan 1, 2013
128 M EUR
19.5 M EUR
15.5 M EUR
Jan 1, 2014
144.86 M EUR
24.05 M EUR
19.77 M EUR
Jan 1, 2015
146.89 M EUR
27.36 M EUR
22.08 M EUR
Jan 1, 2016
184.91 M EUR
23.97 M EUR
19.5 M EUR
Jan 1, 2017
207.48 M EUR
25.59 M EUR
25.64 M EUR
Jan 1, 2018
187.82 M EUR
14.1 M EUR
8.97 M EUR
Jan 1, 2019
214.16 M EUR
18.21 M EUR
14.44 M EUR

Stratec Se Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 12:35 PM
 
REVENUE (M EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
DIV. (EUR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Stratec Se generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stratec Se retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stratec Se's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Stratec Se has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stratec Se's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Stratec Se stock margins

The Stratec Se margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stratec Se. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stratec Se.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
49.79 %
15.13 %
9.24 %
Jan 1, 2006
46.74 %
15.63 %
11.14 %
Jan 1, 2007
55.93 %
20.94 %
14.64 %
Jan 1, 2008
58.94 %
18.2 %
9.82 %
Jan 1, 2009
55.92 %
18.31 %
14.57 %
Jan 1, 2010
53.47 %
16.96 %
12.52 %
Jan 1, 2011
54.84 %
18.37 %
12.89 %
Jan 1, 2012
32.35 %
14.38 %
11.44 %
Jan 1, 2013
32.66 %
15.23 %
12.11 %
Jan 1, 2014
31.02 %
16.6 %
13.65 %
Jan 1, 2015
37.5 %
18.63 %
15.03 %
Jan 1, 2016
33.5 %
12.96 %
10.54 %
Jan 1, 2017
31.21 %
12.33 %
12.36 %
Jan 1, 2018
25.68 %
7.51 %
4.78 %
Jan 1, 2019
23.77 %
8.5 %
6.74 %

Stratec Se Stock Revenue, EBIT, Earnings per Share

The Stratec Se earnings per share therefore indicates how much revenue Stratec Se has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
4.53 EUR
0.69 EUR
0.42 EUR
Jan 1, 2006
6.06 EUR
0.95 EUR
0.68 EUR
Jan 1, 2007
5.99 EUR
1.25 EUR
0.88 EUR
Jan 1, 2008
5.45 EUR
0.99 EUR
0.54 EUR
Jan 1, 2009
7.04 EUR
1.29 EUR
1.03 EUR
Jan 1, 2010
8.87 EUR
1.5 EUR
1.11 EUR
Jan 1, 2011
10.15 EUR
1.86 EUR
1.31 EUR
Jan 1, 2012
10.46 EUR
1.5 EUR
1.2 EUR
Jan 1, 2013
10.85 EUR
1.65 EUR
1.31 EUR
Jan 1, 2014
12.24 EUR
2.03 EUR
1.67 EUR
Jan 1, 2015
12.32 EUR
2.3 EUR
1.85 EUR
Jan 1, 2016
15.49 EUR
2.01 EUR
1.63 EUR
Jan 1, 2017
17.31 EUR
2.14 EUR
2.14 EUR
Jan 1, 2018
15.61 EUR
1.17 EUR
0.75 EUR
Jan 1, 2019
17.75 EUR
1.51 EUR
1.2 EUR

Stratec Se business model & stock analysis

The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry.

Stratec Se SWOT Analysis

Strengths

Stratec SE holds a dominant position in the market, offering unique and innovative products/services that have gained significant traction among customers.

The company possesses strong technological expertise, allowing it to develop cutting-edge solutions that provide a competitive edge over rivals.

Stratec SE boasts an efficient supply chain management system, ensuring timely delivery of products to customers while minimizing costs.

The company invests heavily in research and development, continuously enhancing its product portfolio and offering innovative solutions to meet market demands.

Weaknesses

Stratec SE relies heavily on a few key customers for a significant portion of its revenue, making it vulnerable to potential loss if these customers switch to competitors.

The company's operations are primarily focused in specific geographic regions, limiting its exposure to global markets and potential opportunities.

Stratec SE's product portfolio is relatively narrow, which could limit its ability to cater to diverse customer requirements and adapt to changing market dynamics.

Opportunities

The global medical devices market is experiencing significant growth, presenting Stratec SE with opportunities to expand its customer base and increase revenues.

Advancements in technologies like artificial intelligence and Internet of Things offer Stratec SE the chance to develop innovative solutions and gain a competitive edge in the market.

The company can explore untapped markets and expand its operations internationally, diversifying its customer base and reducing dependency on specific regions or customers.

Threats

The medical devices market is highly competitive, with numerous players vying for market share, which could potentially erode Stratec SE's market position and profitability.

The industry is subject to stringent regulations and compliance requirements, and any changes in regulations could pose challenges for Stratec SE in terms of product development and market access.

Rapid technological advancements may render Stratec SE's existing products/services obsolete if the company fails to adapt and innovate accordingly.

Stratec Se Eulerpool Fair Value

Stratec Se historical P/E ratio, EBIT multiple, and P/S ratio

Stratec Se annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Stratec Se shares outstanding

The number of shares was Stratec Se in 2025 — This indicates how many shares 12.156 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
10.5 M base_Shares
Jan 1, 2006
11.4 M base_Shares
Jan 1, 2007
11.4 M base_Shares
Jan 1, 2008
11.4 M base_Shares
Jan 1, 2009
11.4 M base_Shares
Jan 1, 2010
11.7 M base_Shares
Jan 1, 2011
11.7 M base_Shares
Jan 1, 2012
11.7 M base_Shares
Jan 1, 2013
11.8 M base_Shares
Jan 1, 2014
11.83 M base_Shares
Jan 1, 2015
11.92 M base_Shares
Jan 1, 2016
11.94 M base_Shares
Jan 1, 2017
11.98 M base_Shares
Jan 1, 2018
12.03 M base_Shares
Jan 1, 2019
12.06 M base_Shares

Stratec Se Dividend History

22 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.6EUR↑ 9.1%1×
Jun 30, 20250.6EUR↑ 9.1%1/1
20240.55EUR↓ 43.3%1×
20230.97EUR↑ 2.1%1×
20220.95EUR↑ 5.6%1×
20210.9EUR↑ 7.1%1×
20200.84EUR↑ 2.4%1×
20190.82EUR↑ 2.5%1×
20180.8EUR↑ 3.9%1×
20170.77EUR↑ 2.7%1×
20160.75EUR↑ 7.1%1×

Stratec Se dividend history and estimates

In 2025, Stratec Se paid a dividend amounting to 0.6 EUR. Dividend means that Stratec Se distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2005
0.15 EUR
0 EUR
Jan 1, 2006
0.3 EUR
0 EUR
Jan 1, 2007
0.15 EUR
0 EUR
Jan 1, 2008
0.22 EUR
0 EUR
Jan 1, 2009
0.35 EUR
0 EUR
Jan 1, 2010
0.45 EUR
0 EUR
Jan 1, 2011
0.5 EUR
0 EUR
Jan 1, 2012
0.55 EUR
0 EUR
Jan 1, 2013
0.56 EUR
0 EUR
Invalid Date
0 EUR
0.6 EUR
Jan 1, 2015
0.7 EUR
0 EUR
Jan 1, 2016
0.75 EUR
0 EUR
Jan 1, 2017
0.77 EUR
0 EUR
Jan 1, 2018
0.8 EUR
0 EUR
Jan 1, 2019
0.82 EUR
0 EUR

Stratec Se dividend payout ratio

In 2025, Stratec Se had a payout ratio of 36.57%. The payout ratio indicates the percentage of the company's profits that Stratec Se distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
11.93 %
Jan 1, 2006
14.74 %
Jan 1, 2007
17.24 %
Jan 1, 2008
40.74 %
Jan 1, 2009
34.31 %
Jan 1, 2010
40.18 %
Jan 1, 2011
38.17 %
Jan 1, 2012
46.22 %
Jan 1, 2013
42.75 %
Jan 1, 2014
35.92 %
Jan 1, 2015
37.78 %
Jan 1, 2016
45.92 %
Jan 1, 2017
36.15 %
Jan 1, 2018
108.11 %
Jan 1, 2019
69.35 %
Price targets and forecasts for Stratec Se are not yet available.

Stratec Se Earnings Estimates

Stratec Se Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/5/20221.01EUR78.15 MEUR2022 Q1
11/11/20210.79EUR72.47 MEUR2021 Q3
3/31/20210.84EUR76.13 MEUR2020 Q4
11/5/20200.65EUR60.9 MEUR2020 Q3
8/13/20200.68EUR66.69 MEUR2020 Q2
5/14/20200.48EUR57.85 MEUR2020 Q1
4/2/20200.72EUR60.9 MEUR2019 Q4
8/15/20190.37EUR56.84 MEUR2019 Q2
5/24/20190.32EUR48.16 MEUR2019 Q1
4/19/20180.82EUR67.09 MEUR2017 Q4

EESG©

Eulerpool ESG Scorecard© for the Stratec Se stock

88/100
98
Environment
99
Social
66
Governance
E

Environment

20
Scope 1 - Direct Emissions639.1
Scope 2 - Indirect emissions from purchased energy1,376.7
Scope 3 - Indirect emissions within the value chain9,303.6
Total CO₂ emissions2,015.8
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees36.1
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stratec Se shareholder structure

% Name
40.36645%
Leistner Family
Leistner Family
8.52627%
Brown Capital Management, LLC
Brown Capital Management, LLC
4.22958%
JPMorgan Asset Management U.K. Limited
JPMorgan Asset Management U.K. Limited
3.8249%
Union Investment Privatfonds GmbH
Union Investment Privatfonds GmbH
3.08152%
Juno Investment Partners
Juno Investment Partners
2.48597%
Janus Henderson Investors
Janus Henderson Investors
1.74857%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.57027%
Candriam Luxembourg S.A.
Candriam Luxembourg S.A.
1.48546%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
1.48076%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
...

Stratec Se Executives and Management Board

MW

Mr. Marcus Wolfinger

(57)

Chairman of the Management Board, Chief Executive Officer

Compensation900,000 EUR
CV

Dr. Claus Vielsack

(57)

Member of the Management Board, Director - Product Development

Compensation653,000 EUR
GB

Dr. Georg Bauer

(52)

Director - Sales, Member of the Management Board

Compensation451,000 EUR
PH

Prof. Dr. Georg Heni

(67)

Independent Chairman of the Supervisory Board · since 2022

Compensation96,000 EUR
FH

Dr. Frank Hiller

(59)

Independent Deputy Chairman of the Supervisory Board · since 2019

Compensation76,000 EUR

Stratec Se Supply Chain

Frequently asked questions about Stratec Se

The business model of Stratec SE revolves around providing innovative solutions and services to the diagnostics industry. As a leading global technology partner, Stratec SE specializes in developing and producing automated analyzer systems that enable fast, reliable, and cost-effective diagnostics. By focusing on instrument and assay integration, Stratec SE helps its customers streamline their processes and improve laboratory efficiency. The company's comprehensive portfolio covers a wide range of applications, including clinical diagnostics, blood banking, and pharmaceutical quality control. With its expertise and cutting-edge technologies, Stratec SE aims to drive advancements in diagnostics and contribute to improving patient care worldwide.

All fundamentals and in-depth analysis of Stratec Se

Our stock analysis for Stratec Se Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stratec Se Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Stratec Se Stock
Stratec Se Revenue→
Stratec Se Stock
Stratec Se Net Income→
Stratec Se Stock
Stratec Se P/E→
Stratec Se Stock
Stratec Se P/S→
Stratec Se Stock
Stratec Se EBIT→
Stratec Se Stock
Stratec Se Dividend→
Stratec Se Stock
Stratec Se Directors Dealings→
Stratec Se Stock
Stratec Se Stocks→
Stratec Se Stock
Stratec Se Market capitalization→
Stratec Se Stock
Stratec Se Debt→
Stratec Se Stock
Stratec Se Liabilities→
Stratec Se Stock
Stratec Se Equity→
Stratec Se Stock
Stratec Se AAQS→
Stratec Se Stock
Stratec Se Employees→
Stratec Se Stock
Stratec Se ROE→
Stratec Se Stock
Stratec Se ROA→
Stratec Se Stock
Stratec Se ROCE→